CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 347 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01161173
NCT01161173N/ACompleted
CompareCT.gov

A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting

Hoffmann-La Roche·observational·Posted Jul 13, 2010·Updated Mar 28, 2016

In Brief

An observational study evaluating Erlotinib for Nonsquamous Nonsmall Cell Neoplasm of Lung. Completed, enrolled 347 participants across 36 sites in 2 countries.

Detailed Summary

This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNonsquamous Nonsmall Cell Neoplasm of Lung
CountriesBelgium, Luxembourg
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 13, 2010
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.0 years ago

Interventions

Erlotinibdrug

Erlotinib was provided in the retail versions of the product.